Methods.
A parent or guardian of each study subject gave written informed consent. The protocol is available at http: //www.pedig.net. Eligible subjects were aged 3 to younger than 10 years and had strabismic and/or anisometropic amblyopia, best-corrected visual acuity of 20/32 to 20/63 in the amblyopic eye, interocular visual acuity difference of 2 or more lines, and no improvement in visual acuity in the amblyopic eye between 2 consecutive visits at least 6 weeks apart while patching 6 hours per day or using daily atropine. Spectacles, if prescribed (based on investigator discretion), met the criteria in eTable 1 (http://www .archophthalmol.com). All subjects wore spectacles except 4 with purely strabismic amblyopia. Additional eligibility criteria are listed in eTable 1. Subjects were randomized with equal probability to the following: (1) treatment with 6 hours of prescribed daily patching combined with daily atropine (intensive group); or (2) a reduction of current treatment for 4 weeks with 2 hours of prescribed daily patching or once-weekly atropine followed by spectacles alone if needed (weaning group). Randomization was accomplished using a permuted-blocks design stratified by site and by current treatment with patching or atropine. The primary outcome was masked assessment of visual acuity by isolated crowded Amblyopia Treatment Study HOTV (for subjects aged 3 to Ͻ7 years) 3 or Electronic Early Treatment Diabetic Retinopathy Study (for subjects aged 7 to Ͻ10 years) 4 optotypes at 10 weeks. Subjects in the intensive treatment group discontinued using atropine 2 weeks before this examination. The planned sample size was 240. After a recruitment period of 18 months, 55 subjects had been randomized at 18 sites. The study was stopped on recommendation of the data and safety monitoring committee because of slow recruitment and a conditional power analysis indicating that the study was unlikely to find a statistically significant benefit of intensive treatment if the study continued.
Results. Between October 1, 2007, and March 30, 2009, 27 subjects were randomized to the intensive group and 28 were randomized to the weaning group. The average age was 6.9 years; 25 subjects (45%) were female; and 40 subjects (73%) were white. At the time of enrollment, 39 subjects (71%) were being treated with patching and 16 (29%) were being treated with daily atropine. The 2 groups appeared balanced with respect to baseline characteristics (eTable 2), except that those in the intensive group were more likely than those in the Abbreviation: CI, confidence interval. a Visual acuity testers were masked for the primary outcome examination. b P=.30 for the difference between treatment groups in the proportion of subjects with improvement of 2 or more lines from logistic regression controlling for baseline visual acuity. One subject missing the primary outcome examination in the weaning group was considered to have not improved 2 or more lines for analyses.
c The difference is calculated as intensive minus weaning. A negative difference favors the weaning group.
weaning group to have anisometropia or combined mechanism as the cause of amblyopia (17 subjects [63%] vs 12 subjects [43%], respectively) and had more hyperopia in the amblyopic eye (mean spherical equivalent, 5.39 vs 4.24 diopters, respectively).
At the 10-week primary outcome examination, visual acuity in the amblyopic eye improved 2 or more lines from enrollment in 3 of the 27 subjects (11%) in the intensive treatment group and 6 of the 27 subjects (22%) in the weaning group (difference in proportions=−10%; 95% confi- dence interval, −30% to ϩ9%) (Table) . Improvement in visual acuity in the amblyopic eye averaged 0.5 logMAR line in both groups (treatment group difference in mean logMAR lines adjusted for baseline visual acuity=0.0; 95% confidence interval, −0.7 to ϩ0.7) (Table) . After adjusting for sex, cause of amblyopia, refractive error in the amblyopic eye, and visual acuity testing method (Amblyopia Treatment Study HOTV testing protocol 3 vs Electronic Early Treatment Diabetic Retinopathy Study testing protocol 4 ), results were similar (data not shown).
Clinical Sites That Participated in This Protocol
Comment. For children with amblyopia who have already stopped improving with 6 hours of prescribed daily patching or with daily atropine, we found that an intensive final push of combined treatment with patching and atropine did not produce a better visual acuity outcome after 10 weeks compared with a control group in whom treatment was gradually discontinued. Despite our small sample size, it is unlikely that a meaningful effect was missed, since both the upper and lower limits of the 95% confidence interval for the mean difference between treatment groups were less than 1 line.
This study evaluated a select group of children with mild residual amblyopia (visual acuity of 20/32-20/63 inclusive) who had a substantial amount of previous amblyopia treatment. Our results should not be generalized to children with more severe residual amblyopia or those who have stopped improving after less intense treatment. 
